ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2

Huebner, Kerstin
Erlenbach-Wuensch, Katharina
Prochazka, Jan
Sheraj, Ilir
Hampel, Chuanpit
Mrazkova, Blanka
Michalcikova, Tereza
Tureckova, Jolana
Iatsiuk, Veronika
Weissmann, Anne
Ferrazzi, Fulvia
Kunze, Philipp
Nalli, Enise
Sammer, Elisabeth
Gehring, Annemarie
Cheema, Marie M.
Eckstein, Markus
Paap, Eva-Maria
Soederberg, Agnes
Fischer, Corinna
Paul, Sushmita
Mahadevan, Vijayalakshmi
Ndreshkjana, Benardina
Meier, Melanie A.
Muehlich, Susanne
Geppert, Carol I.
Merkel, Susanne
Grutzmann, Robert
Roehe, Adriana
Banerjee, Sreeparna
Hartmann, Arndt
Sedlacek, Radislav
Schneider-Stock, Regine
In cancer, the activating transcription factor 2 (ATF2) has pleiotropic functions in cellular responses to growth stimuli, damage, or inflammation. Due to only limited studies, the significance of ATF2 in colorectal cancer (CRC) is not well understood. We report that low ATF2 levels correlated with worse prognosis and tumor aggressiveness in CRC patients. NanoString gene expression and ChIP analysis confirmed trophoblast cell surface antigen 2 (TROP2) as a novel inhibitory ATF2 target gene. This inverse correlation was further observed in primary human tumor tissues. Immunostainings revealed that high intratumoral heterogeneity for ATF2 and TROP2 expression was sustained also in liver metastasis. Mechanistically, our in vitro data of CRISPR/Cas9-generated ATF2 knockout (KO) clones revealed that high TROP2 levels were critical for cell de-adhesion and increased cell migration without triggering EMT. TROP2 was enriched in filopodia and displaced Paxillin from adherens junctions. In vivo imaging, micro-computer tomography, and immunostainings verified that an ATF2KO/TROP2high status triggered tumor invasiveness in in vivo mouse and chicken xenograft models. In silico analysis provided direct support that ATF2low/TROP2high expression status defined high-risk CRC patients. Finally, our data demonstrate that ATF2 acts as a tumor suppressor by inhibiting the cancer driver TROP2. Therapeutic TROP2 targeting might prevent particularly the first steps in metastasis, i.e., the de-adhesion and invasion of colon cancer cells.
Cellular and Molecular Life Sciences


ALCAM (Activated Leukocyte Cell Adhesion Molecule)
Yavuz, Esra; ÖYKEN, MERVE; Erson Bensan, Ayşe Elif (2018-01-01)
ALCAM (Activated Leukocyte Cell Adhesion Molecule), also known as CD166 (cluster of differentiation 166), is a member of a subfamily of immunoglobulin receptors with five immunoglobulin-like domains (VVC2C2C2) in the extracellular domain.
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers.
Cicek, Esra; Circir, Ayca; Oyken, Merve; Akbulut Caliskan, Ozge; Dioken, Didem Naz; Guntekin Ergun, Sezen; Cetin-Atalay, Rengul; Sapmaz, Aysegul; Ovaa, Huib; Sahin, Ozgur; Erson Bensan, Ayşe Elif (2021-10-30)
Epidermal growth factor receptor (EGFR) has critical roles in epithelial cell physiology. Over-expression and over-activation of EGFR have been implicated in diverse cancers, including triple-negative breast cancers (TNBCs), prompting anti‐EGFR therapies. Therefore, developing potent therapies and addressing the inevitable drug resistance mechanisms necessitates deciphering of EGFR related networks. Here, we describe Sorting Nexin 3 (SNX3), a member of the recycling retromer complex, as a critical player in...
miR-770-5p regulates EMT and invasion in TNBC cells by targeting DNMT3A
Noyan, Senem; Andaç Özketen, Ayşe; Gurdal, Hakan; Gur Dedeoglu, Bala (2021-07-01)
MicroRNAs (miRNAs) are shown to regulate various processes in cancer like motility and invasion that are key features of the metastatic triple negative breast cancer (TNBCs). Epithelial-mesenchymal transition (EMT) is one of the well-defined cellular transitioning processes characterized with reduced E-cadherin expression and increased mesenchymal molecules such as Vimentin or Snail thereby gives the cells mobility and invasive character. Aberrant DNA methylation by DNA methyltransferases (DNMTs) plays an i...
DynaDom: structure-based prediction of T cell receptor inter-domain and T cell receptor-peptide-MHC (class I) association angles
Hoffmann, Thomas; Marıon, Antoıne; Antes, Iris (Springer Science and Business Media LLC, 2017-02-02)
Background: T cell receptor (TCR) molecules are involved in the adaptive immune response as they distinguish between self- and foreign-peptides, presented in major histocompatibility complex molecules (pMHC). Former studies showed that the association angles of the TCR variable domains (Va/V beta) can differ significantly and change upon binding to the pMHC complex. These changes can be described as a rotation of the domains around a general Center of Rotation, characterized by the interaction of two highly...
Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes.
Erikçi, E; Gürsel, Mayda; Gürsel, I (2011-02-01)
The immunogenicity of a vaccine formulation is closely related to the effective internalization by the innate immune cells that provide prolonged and simultaneous delivery of antigen and adjuvant to relevant antigen presenting cells. Endosome associated TLR9 recognizes microbial unmethylated CpG DNA. Clinical applications of TLR9 ligands are significantly hampered due to their pre-mature in vivo digestion and rapid clearance. Liposome encapsulation is a powerful tool to increase in vivo stability as well as...
Citation Formats
K. Huebner et al., “ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2,” Cellular and Molecular Life Sciences, vol. 79, no. 8, pp. 0–0, 2022, Accessed: 00, 2022. [Online]. Available: